 |
|
|
|
|
With Hormone Therapy, Tender Breasts May Signal Cancer Risk
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 The findings apply only to women taking the combination therapy, not women who've had hysterectomies and are taking estrogen alone, Crandall said.
In a statement, Wyeth Pharmaceuticals, which makes the estrogen-progestin therapy Prempro, called the study "interesting" but added that, "breast tenderness is not an established risk factor for breast cancer." According to the company, up to a quarter of women who take combination hormone therapy will develop some tenderness in the breast, typically transient. The company also noted that the "small" increase in breast cancer risk for women on combo therapy and those on placebo, "has previously been reported and is included in the Prescribing Information (labeling) for Prempro."
More information
Text Continues Below
The U.S. National Heart, Lung and Blood Institute has more on menopausal hormone therapy.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 10/12/2009
|
|
SOURCES: Carolyn Crandall, M.D., clinical professor, general internal medicine and health services research, David Geffen School of Medicine, University of California, Los Angeles, and faculty member, Iris Cantor-UCLA Women's Health Center; Mary B. Daly, M.D., Ph.D., director, Personalized Cancer Risk Assessment Program, Fox Chase Cancer Center, Philadelphia; Oct. 12, 2009, news statement, Wyeth Pharmaceuticals; Oct. 12, 2009, Archives of Internal Medicine
|
.gif)
